hsa-mir-299: Hsa-mir-299 is a microRNA that has been identified in various studies to be associated with estrogen signaling [PMC4206873]. It is part of a predictive signature that includes other miRNAs such as hsa-miR-135b, hsa-miR-190, hsa-miR-217, hsa-miR-218, and hsa-miR-342 [PMC5123339]. Hsa-mir-299 and its variants have also been found to be associated with esophageal neoplasms [PMC9483142]. It has been shown to bind to hsa_circ_0065898 and play roles in various diseases [PMC8797878]. The expression of hsa-mir-299 has been associated with poor prognosis in certain diseases [PMC8797878]. In research studies, the expression of hsa-mir-299 has been manipulated using constructs such as pIRES2-EGFP and pMIR-Report vector [PMC3829031]. Hsa-mir-299 has also been found to have different roles in different diseases, acting as a tumor suppressor in hepatocellular carcinoma (HCC) but associated with poor prognosis in esophageal carcinoma (EC) patients [PMC7467934] [PMC9200351]. It is also involved in the suppression of key target genes associated with HCV-host interactions and may have potential targets such as ATG5, PRKAA1, MYCN, ITGB3BP, and PDGFRbeta [PMC8615810]. Furthermore, it has been predicted to target genes related to Alzheimer's disease (AD) based on microRNA-target analysis studies [PMC9312389]. The expression of hsa-mir-299 is specific to adenomas and advanced carcinoma but not expressed in AEC (adenocarcinoma) cells [PMC7764749].